Renal and cardiovascular characterization of COX-2 knockdown mice.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Physiology. Regulatory Integrative and Comparative Physiology

• Publication date

  2009-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajpregu.90985.2008PMID 19357295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.

  2008cited by this paper
• Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis

  2008cited by this paper
• COX-2 inhibitors and cardiovascular risk.

  2007cited by this paper
• COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation

  2007cited by this paper
• Targeted Cyclooxygenase Gene (Ptgs) Exchange Reveals Discriminant Isoform Functionality*

  2007cited by this paper
• Stronger inhibition by nonsteroid anti‐inflammatory drugs of cyclooxygenase‐1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events

  2006cited by this paper
• Genetic model of selective COX2 inhibition reveals novel heterodimer signaling

  2006cited by this paper
• Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function.

  2006cited by this paper
• Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition.

  2005cited by this paper
• COX-2–Derived Prostacyclin Modulates Vascular Remodeling

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.

  2005cited by this paper
• Low-dose aspirin for the prevention of atherothrombosis.

  2005cited by this paper
• Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

  2005cited by this paper
• Prostacyclin protects against elevated blood pressure and cardiac fibrosis.

  2005cited by this paper
• Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice.

  2005cited by this paper
• Lipopolysaccharide induces 5-lipoxygenase-activating protein gene expression in THP-1 cells via a NF-kappaB and C/EBP-mediated mechanism.

  2005cited by this paper
• COX-2 inhibitors and cardiovascular risk.

  2005cited by this paper
• Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance.

  2004cited by this paper
• Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2–Derived Prostaglandins

  2004cited by this paper
• Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2

  2002cited by this paper
• Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse

  2002cited by this paper
• Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries

  2001cited by this paper
• The coxibs, selective inhibitors of cyclooxygenase-2.

  2001cited by this paper
• Prostaglandins and leukotrienes: advances in eicosanoid biology.

  2001cited by this paper
• The coxibs, selective inhibitors of cyclooxygenase-2.

  2001cited by this paper
• Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.

  2000cited by this paper
• Cyclooxygenases: structural, cellular, and molecular biology.

  2000cited by this paper
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

  1999cited by this paper
• Renal effects of selective cyclooxygenase‐2 inhibition in normotensive salt‐depleted subjects

  1999cited by this paper
• Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

  1999cited by this paper
• Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

  1997cited by this paper
• Specification of the anterior hindbrain and establishment of a normal mid/hindbrain organizer is dependent on Gbx2 gene function.

  1997cited by this paper
• Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse.

  1995cited by this paper
• Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II

  1995cited by this paper
• Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.

  1994cited by this paper
• Metabolic disposition of prostacyclin in humans.

  1983cited by this paper
• Relevance of urinary 6-keto-prostaglandin F1α determination

  1981cited by this paper
• Relevance of urinary 6-keto-prostaglandin F1 alpha determination.

  1981cited by this paper
• Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

  1971cited by this paper

• COX2-independent and COX2-dependent effects of naproxen on bone quality, osteocytes, and fatigue fracture healing in male and female mice

  2025cites this paper
• Prostaglandin endoperoxide synthase 2 regulates neuroinflammation to mediate postoperative cognitive dysfunction in mice

  2025cites this paper
• New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases

  2021cites this paper
• Expression of neuronal nitric oxide synthase and renin in dysplastic kidneys of young dogs

  2021cites this paper
• Cardio-renal safety of non-steroidal anti-inflammatory drugs.

  2019cites this paper
• Perivascular adipose tissue–derived extracellular vesicle miR‐221‐3p mediates vascular remodeling

  2019cites this paper
• Early B Cell Factor 1 (EBF1) Regulates Glomerular Development by Controlling Mesangial Maturation and Consequently COX-2 Expression.

  2019cites this paper
• Comprehensive review of cardiovascular toxicity of drugs and related agents

  2018cites this paper
• Prostaglandin‐endoperoxide synthase 2 (cyclooxygenase‐2), a complex target for colorectal cancer prevention and therapy

  2018cites this paper
• Autism‐related behaviors in the cyclooxygenase‐2‐deficient mouse model

  2018cites this paper
• Differential compensation of two cyclooxygenases in renal homeostasis is independent of prostaglandin‐synthetic capacity under basal conditions

  2018cites this paper
• Analysis of Excessive Homozygous Regions in Rhodesian Ridgeback Dogs

  2017influential citation
• Flipping the cyclooxygenase (Ptgs) genes reveals isoform-specific compensatory functions1,2[S]

  2017cites this paper
• Genomic and lipidomic analyses differentiate the compensatory roles of two COX isoforms during systemic inflammation in mice1,2[S]

  2017cites this paper
• Nonsteroidal anti-inflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts

  2017cites this paper
• Platelet Prostanoids and their receptors

  2017cites this paper
• COX-2 gene dosage-dependent defects in kidney development.

  2016cites this paper
• Low expression of cyclooxygenase-2 in chronic kidney disease in young dogs.

  2016cites this paper
• Functional analysis of epithelium-specific Ets transcription factor-1 in inflammation

  2016cites this paper
• Animal models of myocardial infarction: Mainstay in clinical translation.

  2016cites this paper
• Biomechanical forces promote blood development through prostaglandin E2 and the cAMP–PKA signaling axis

  2015cites this paper
• 12-hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor

  2014cites this paper
• Angiotensin-(1-7)/Mas Axis Compensates Absent Bradykinin in Bdkrb2 -/- and Klkb1 -/- Mice to Regulate Thrombosis Risk

  2014cites this paper
• Allelic variation in the canine Cox-2 promoter causes hypermethylation of the canine Cox-2 promoter in clinical cases of renal dysplasia

  2014cites this paper
• Cyclooxygenase‐2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4)

  2013cites this paper
• Deletion of cyclooxygenase-2 in the mouse increases arterial blood pressure with no impairment in renal NO production in response to chronic high salt intake.

  2013cites this paper
• Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis.

  2013cites this paper
• Cyclooxygenase Pathway of the Arachidonate Cascade

  2012cites this paper
• Cyclooxygenase (COX) Inhibitors and the Newborn Kidney

  2012cites this paper
• Cyclooxygenase-2–Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a Sirtuin-1–Dependent-Manner

  2012cites this paper
• Prostaglandin receptor EP4 in abdominal aortic aneurysms.

  2012cites this paper
• Targeted exchange of an expression cassette encoding cyclooxygenase-2 at the Ptgs1 locus.

  2012cites this paper
• Novel Porcine Models of Myocardial Ischemia/Infarction – Technical Progress, Modified Electrocardiograms Validating, and Future Application

  2012cites this paper
• Cyclooxygenase-2-Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a SIRT1-Dependent-Manner Running title: Barbieri et al.; Prostacyclin regulates thrombosis via SIRT1

  2012cites this paper
• Effect of Evening Primrose Oil and Omega-3 Polyunsaturated Fatty Acids on the Cardiovascular Risk of Celecoxib in Rats

  2011cites this paper
• Pulmonary Oxidative Stress Is Increased in Cyclooxygenase-2 Knockdown Mice with Mild Pulmonary Hypertension Induced by Monocrotaline

  2011influential citation
• Defects in mouse nephrogenesis induced by selective and non‐selective cyclooxygenase‐2 inhibitors

  2011cites this paper
• Cyclo-oxygenase-2 knockout genotype in mice is associated with blunted angiotensin II-induced oxidative stress and hypertension.

  2011cites this paper
• Novel Allelic Variants in the Canine Cyclooxgenase-2 (Cox-2) Promoter Are Associated with Renal Dysplasia in Dogs

  2011cites this paper
• Emotion recollected in tranquility: lessons learned from the COX-2 saga.

  2010cites this paper
• Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis

  2010influential citation
• Nitric oxide-mediated negative regulation of cyclooxygenase-2 induction in vascular inflammation.

  2010cites this paper
• Current world literature.

  2010cites this paper
• Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli.

  2010cites this paper
• Modulating P‐glycoprotein regulation: Future perspectives for pharmacoresistant epilepsies?

  2010cites this paper
• Cyclooxygenase-2–Dependent Prostacyclin Formation and Blood Pressure Homeostasis: Targeted Exchange of Cyclooxygenase Isoforms in Mice

  2010influential citation
• Nonsteroidal Anti-Inflammatory Drugs and the Kidney

  2010cites this paper
• A cell-based assay for screening lipoxygenase inhibitors.

  2009cites this paper
• The Journal of Toxicological Sciences

  2009influential citation
• Enhanced cyclooxygenase 2‐mediated vasodilatation in coronary arteries from insulin resistant obese Zucker rats

  2009cites this paper